Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
- 16 July 1990
- journal article
- research article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
- Vol. 1045 (2), 115-120
- https://doi.org/10.1016/0005-2760(90)90139-o
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)Atherosclerosis, 1989
- Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbitsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
- CS-514 Suppresses Plasma Triglyceride in Hypertriglyceridemic Subjects Without Modifying a Lipoprotein Structural ModelHormone and Metabolic Research, 1987
- PROBUCOL VERSUS EPTASTATIN IN HYPERCHOLESTEROLAEMIC DIABETICSThe Lancet, 1986
- The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy VolunteersAtherosclerosis, 1986
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B)The Journal of Antibiotics, 1983
- Microbial hydroxylation of ML-236B (compactin) Studies on microorganisms capable of 3.BETA.-hydroxylation of ML-236B.The Journal of Antibiotics, 1983
- Regulation of HMG-CoA ReductaseAdvances in Lipid Research, 1976
- ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.The Journal of Antibiotics, 1976